Breast Cancer Now media statements
Talazoparib (Talzenna) approved for use on the NHS in England
Responding to the National Institute of Health and Care Excellence (NICE) decision, Baroness Delyth Morgan, chief executive at Breast Cancer...
Scottish Medicines Consortium (SMC) approves trastuzumab deruxtecan (Enhertu) for use on NHS in Scotland
Baroness Delyth Morgan, chief executive at Breast Cancer Now, said:
We respond to a policy review by leading cancer experts, published in The Lancet Oncology, on improving cancer care in the UK
Responding to a Policy Review by leading cancer experts, published in The Lancet Oncology, on improving cancer care in the UK, Baroness Dely...
We respond to NHSE announcement of the license for anastrozole being extended to cover its use as a risk-reducing treatment for breast cancer
Baroness Delyth Morgan, chief executive at Breast Cancer Now, said:
Breast Cancer Now responds to research about polygenic risk score tests
In response to research published in BMJ Medicine*, Dr Kotryna Temcinaite, head of research communications at Breast Cancer Now, said:
Breast Cancer Now responds to 'life-saving’ decision to approve olaparib for use on the NHS in Scotland
Baroness Delyth Morgan, chief executive at Breast Cancer Now, said:
We respond to the Scottish Health Technologies Group’s recommendation on tumour profiling tests for certain patients with primary breast cancer
Melanie Sturtevant, associate director of policy, evidence and influencing, at Breast Cancer Now, said:
We respond to new research exploring if a robot device could potentially carry out a clinical breast exam
In response to new research by the University of Bristol that a robot could help diagnose breast cancer early, Dr Kotryna Temcinaite, head o...
We respond to July’s cancer waiting times from NHS Wales
Melanie Sturtevant, associate director of policy, evidence and influencing at Breast Cancer Now, said:
We respond to provisional rejection of trastuzumab deruxtecan (Enhertu) for certain secondary breast cancer patients
Baroness Delyth Morgan, chief executive at Breast Cancer Now, said:
We respond to July’s NHS England waiting times data
Baroness Delyth Morgan, chief executive at Breast Cancer Now, said:
We respond to new CRUK analysis revealing over a million lives have been saved over last four decades in the UK due to advances in cancer care
Baroness Delyth Morgan, chief executive at Breast Cancer Now, said: